The Effect of Chinese Herbal Medicine Gualouxiebaibanxia Decoction for the Treatment of Angina Pectoris: A Systematic Review

We systematically assess the current clinical evidence of Gualouxiebaibanxia (GLXBBX) decoction for the treatment of angina pectoris (AP). We included RCTs testing GLXBBX against conventional drugs and GLXBBX combined with conventional drugs versus conventional drugs. 19 RCTs involving 1730 patients were finally identified, and the methodological quality was evaluated as generally low. The results of the meta-analysis showed that GLXBBX alone had significant effect on improving angina symptoms (RR: 1.24, 95% CI 1.14 to 1.35; P < 0.00001), ECG (RR: 1.28 [1.13,1.44]; P < 0.0001), and HDL-C (MD: 0.56 [0.54,0.58]; P < 0.00001) compared with anti-arrhythmic drugs. A significant improvement in angina symptoms (RR: 1.17 [1.12,1.22]; P < 0.00001) and ECG (RR = 1.22; 95% CI = [1.14,1.30]; P < 0.00001) was observed for GLXBBX plus conventional drugs when compared with conventional drugs. Eight trials reported adverse events without serious adverse effects. GLXBBX appears to have beneficial effects on improvement of ECG and reduction of angina symptoms in participants with AP. However, the evidence remains weak due to the poor methodological quality of the included studies. More rigorous trials are needed to confirm the results.

[1]  J. H. Lee,et al.  Interactions between the APOA5 -1131T>C and the FEN1 10154G>T polymorphisms on ω6 polyunsaturated fatty acids in serum phospholipids and coronary artery disease , 2010, Journal of Lipid Research.

[2]  Mark A Hlatky,et al.  Medical Costs and Quality of Life 10 to 12 Years After Randomization to Angioplasty or Bypass Surgery for Multivessel Coronary Artery Disease , 2004, Circulation.

[3]  J. Kanu,et al.  Single nucleotide polymorphism rs3774261 in the AdipoQ gene is associated with the risk of coronary heart disease (CHD) in Northeast Han Chinese population: a case-control study , 2016, Lipids in Health and Disease.

[4]  Bernadette A. Thomas,et al.  Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 , 2015, The Lancet.

[5]  Y. Wee,et al.  Medical management of chronic stable angina. , 2015, Australian prescriber.

[6]  X. Xiong,et al.  Qigong for Hypertension: A Systematic Review , 2015 .

[7]  X. Yao,et al.  [Study on the active spirostanol saponins of Gualou xiebai baijiutang]. , 2003, Yao xue xue bao = Acta pharmaceutica Sinica.

[8]  Jean-Claude Tardif,et al.  Coronary artery disease in 2010 , 2010 .

[9]  Guanghui Liu,et al.  The association between blood lipid and phlegm turbidity syndrome of angina pectoris: a systematic review and meta-analysis. , 2014, Complementary therapies in medicine.

[10]  Min-Jeong Shin,et al.  Alteration in Metabolic Signature and Lipid Metabolism in Patients with Angina Pectoris and Myocardial Infarction , 2015, PloS one.

[11]  Yong Woo Lee,et al.  Unsaturated fatty acids selectively induce an inflammatory environment in human endothelial cells. , 2002, The American journal of clinical nutrition.

[12]  이은직.  The association of specific metabolites of lipid metabolism with markers of oxidative stress, inflammation and arterial stiffness in men with newly diagnosed type 2 diabetes. , 2012 .

[13]  F. Liang,et al.  Acupoint Application in Patients with Chronic Stable Angina Pectoris: Study Protocol of a Randomized, Double-Blind, Controlled Trial , 2014, Evidence-based complementary and alternative medicine : eCAM.

[14]  R. Choudhary,et al.  Contribution of various lipid profile parameters in determining creatine kinase-MB levels in unstable angina patients , 2016, International journal of applied & basic medical research.

[15]  D. Mozaffarian,et al.  Defining and Setting National Goals for Cardiovascular Health Promotion and Disease Reduction: The American Heart Association's Strategic Impact Goal Through 2020 and Beyond , 2010, Circulation.

[16]  Tai-hui Fang,et al.  Gualou Xiebai Decoction prevents myocardial fibrosis by blocking TGF‐beta/Smad signalling , 2013, The Journal of pharmacy and pharmacology.

[17]  M. Mattson,et al.  Linoleic acid and TNF-alpha cross-amplify oxidative injury and dysfunction of endothelial cells. , 1996, Journal of lipid research.

[18]  J. Camm,et al.  [Guidelines on the management of stable angina pectoris: executive summary]. , 2006, Giornale italiano di cardiologia.

[19]  C. Tracy,et al.  ACC/AHA PRACTICE GUIDELINES ACC/AHA Guidelines for Ambulatory Electrocardiography , 1999 .

[20]  Alan D. Lopez,et al.  The Global Burden of Disease Study , 2003 .

[21]  J. Spertus,et al.  Hospital-Level Variation in Angina and Mortality at 1 Year After Myocardial Infarction: Insights From the Translational Research Investigating Underlying Disparities in Acute Myocardial Infarction Patients’ Health Status (TRIUMPH) Registry , 2014, Circulation. Cardiovascular quality and outcomes.

[22]  Hai-yan Zhu,et al.  Gualou xiebai banxia decoction inhibits NF-kappa B-dependent inflammation in myocardial ischemia-reperfusion injury in rats. , 2011, Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan.

[23]  Sankey V. Williams,et al.  ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina). , 2003, Circulation.

[24]  M. de Oya,et al.  Effect of dietary fat saturation on LDL oxidation and monocyte adhesion to human endothelial cells in vitro. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[25]  X. Xiong,et al.  Qigong for Hypertension , 2015, Medicine.

[26]  D. Orme-Johnson,et al.  Prevention and Treatment of Cardiovascular Disease in Adolescents and Adults through the Transcendental Meditation(®) Program: A Research Review Update. , 2012, Current hypertension reviews.

[27]  T. Münzel,et al.  Nitrate therapy and nitrate tolerance in patients with coronary artery disease. , 2013, Current opinion in pharmacology.

[28]  Nomenclature and criteria for diagnosis of ischemic heart disease. Report of the Joint International Society and Federation of Cardiology/World Health Organization task force on standardization of clinical nomenclature. , 1979, Circulation.

[29]  L. Tavazzi,et al.  Predicting prognosis in stable angina—results from the Euro heart survey of stable angina: prospective observational study , 2006, BMJ : British Medical Journal.

[30]  M. Kallistratos,et al.  Treatment of Stable Angina Pectoris With Ivabradine in Everyday Practice: A Pan‐Hellenic, Prospective, Noninterventional Study , 2015, Clinical cardiology.

[31]  C. Vlachopoulos,et al.  Ranolazine for the symptomatic treatment of patients with chronic angina pectoris in Greece: a cost-utility study , 2015, BMC Health Services Research.

[32]  A. Seidler,et al.  The role of psychosocial stress at work for the development of cardiovascular diseases: a systematic review , 2011, International Archives of Occupational and Environmental Health.

[33]  J. Kaski,et al.  Pharmacological treatment of chronic stable angina pectoris. , 2013, Clinical medicine.

[34]  E. Braunwald,et al.  Unstable Angina: Is It Time for a Requiem? , 2013, Circulation.

[35]  J. Spertus,et al.  The prevalence of weekly angina among patients with chronic stable angina in primary care practices: The Coronary Artery Disease in General Practice (CADENCE) Study. , 2009, Archives of internal medicine.

[36]  G. Mancia,et al.  Guidelines on the management of stable angina pectoris: executive summary: the task force on the management of stable angina pectoris of the European society of cardiology. , 2006, European heart journal.

[37]  Hyunsu Bae,et al.  Evidence Based Complementary and Alternative Medicine , 2008, Evidence-based complementary and alternative medicine : eCAM.